Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6857 | NS 398 |
| Selective cyclooxygenase-2 inhibitor (IC50 values are 3.8 and > 100 μM for COX-2 and COX-1 respectively). Induces apoptosis in colorectal tumor cells and elevates COX-2 protein expression in vitro. Orally active and non-ulcerogenic analgesic and anti-inflammatory in vivo. | |
| BCC6858 | WB 4101 hydrochloride |
| α1A-adrenergic selective antagonist. Also available as part of the α1-Adrenoceptor. | |
| BCC6859 | Zaprinast |
| Phosphodiesterase inhibitor, selective for PDE6, 5, 11 and 9 (IC50 values are 0.15, 0.76, 12.0 and 29.0 μM respectively). Putative GPR35 agonist. | |
| BCC6860 | BRL 37344, sodium salt |
| Potent and selective β3 adrenoceptor agonist (Ki values are 287, 1750 and 1120 nM for β3, β1 and β2 receptors respectively). Also available as part of the β-Adrenoceptor Agonist. | |
| BCC6861 | Xamoterol hemifumarate |
| β1-adrenoceptor-selective partial agonist (pA2 values are 7.4 - 7.8 and 5.2 - 6.2 at β1- and β2-adrenoceptors respectively). | |
| BCC6863 | BD 1047 dihydrobromide |
| σ1 receptor antagonist, exhibiting a similar binding profile to that of BD 1063 but with higher affinity (approximately 10-fold) at both σ1 and σ2 sites. | |
| BCC6866 | SYM 2206 |
| Novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ). Acts allosterically at the same regulatory site as GYKI 52466 and 53655 and other benzodiazepines but does not bind to the central diazepine binding site. Selective for AMPA relative to kainate receptor sub-types. Similar potency to GYKI 53655. Anticonvulsant in vivo. | |
| BCC6868 | Diazoxide |
| Antihypertensive, activates ATP-dependent K+ channels (Kir6). Induces activation of PKCε, an intermediate in the opening of mitoKATP channels, results in cardioprotection against hypoxia-induced death. Blocks desensitization of AMPA receptors. | |
